Loading data for APLM — first visit, this takes a few seconds.
Apollomics Inc. (APLM)
NasdaqCM: APLM
· Echtzeitkurs · USD
23.55
+0.15 (0.64%)
Zum Schluss: Aug 17, 2026, 8:00 PM
26.61
+12.99%
Vorbörslich: 7:30 AM
Apollomics Inc. (APLM) Stock Price, Analysis & Data
0.64% (1D)
Keine Daten verfügbar
| Geld | 23.2 |
| Marktkapitalisierung | 68.2 Mio |
| Umsatz (TTM) | 8.84 Mio |
| Nettogewinn (TTM) | -10.94 Mio |
| Beta | 1.45 |
| EPS (ttm) | -7.62 |
| KGV (TTM) | n/a |
| Forward-KGV | -36.23 |
| KBV (TTM) | -15.86 |
| KUV (TTM) | 7.71 |
| Earnings Date | n/a |
| Brief | 23.65 |
| Volumen | 34,987 |
| Ø Vol. (20D) | 25,196 |
| Eröffnung | 22.96 |
| Vortagesschluss | 23.40 |
| Tagesspanne | 22.33 - 25.50 |
| 52-Wk Range | 3.66 - 42.12 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über APLM
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulati...
Branche Biotechnology
Sektor Healthcare
IPO Datum Nov 26, 2021
Mitarbeiter 14
Börse NasdaqCM
Tickersymbol APLM
Website https://www.apollomicsinc.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Apollomics 8.5 Mio, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -10.94 Mio, ein Rückgang von -79.69 %.
Finanzberichte